Company news

NanoViricides, Inc. news in 2026

NanoViricides, Inc.'s news releases, calls and decks from 2026, newest first.

View company

As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides

October 27, 2026

NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials

October 20, 2026

Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides

October 13, 2026

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides

September 15, 2026

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

September 8, 2026

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

August 18, 2026

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

August 10, 2026

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola

July 22, 2026

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

July 13, 2026

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

July 6, 2026

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

June 29, 2026

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

June 22, 2026

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

June 15, 2026

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

May 18, 2026

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides

May 18, 2026

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II

May 15, 2026

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

May 6, 2026

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

April 7, 2026

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides

April 1, 2026

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

March 11, 2026

NanoViricides: Fiscal Q2 Earnings Snapshot

February 17, 2026

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

February 12, 2026

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

February 10, 2026

NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference

January 20, 2026

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

January 13, 2026

Decks in 2026